文献速递乳房整形与再造显微修复重建

加速康复外科方案减少腹部皮瓣显微乳房再造患者门诊阿片类药物使用

Enhanced Recovery after Surgery Protocols Decrease Outpatient Opioid Use in Patients Undergoing Abdominally Based Microsurgical Breast Reconstruction.
PubMed 文献 · Plast Reconstr Surg · 2020-01-01

该回顾性研究比较了ERAS实施前后接受腹部皮瓣显微乳房再造患者的门诊阿片类药物使用与恢复情况。共纳入105例患者(ERAS前46例,ERAS后59例),ERAS组门诊吗啡毫克当量总量显著低于ERAS前组(337.5 vs 668.8,p=0.016),且术后第1周差异显著(p=0.044),但疼痛评分相当。结论提示ERAS获益可延伸至门诊环境。

要点

  • ERAS组门诊阿片类药物总量显著低于ERAS前组(p=0.016)。
  • 差异在术后第1周显著(p=0.044),后续周逐渐趋同。
  • 尽管阿片用量更少,ERAS组疼痛评分与ERAS前组相当。

核心结论

  • ERAS方案的获益可延伸至门诊环境,支持其用于促进恢复并帮助应对处方阿片滥用问题。

研究设计与样本

  • 回顾性研究,比较ERAS实施前后接受腹部皮瓣显微乳房再造的患者,共105例(ERAS前46例,ERAS后59例)。

主要发现

  • ERAS组门诊吗啡毫克当量总用量低于ERAS前组(337.5 vs 668.8,p=0.016)。
  • 差异在术后第1周显著(p=0.044),后续周逐渐趋同。
  • ERAS组阿片用量显著更少,但疼痛评分与ERAS前组相当。

关键数值与推荐

  • 俄亥俄州法律规定一次处方阿片类药物不超过7天,所有处方细节记录于全州报告系统,据此确定阿片使用量。

临床怎么用

  • 在腹部皮瓣显微乳房再造患者中实施ERAS方案,可减少门诊阿片类药物使用而不增加疼痛评分。

局限性

  • 回顾性研究设计,证据等级为治疗性III级。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Enhanced recovery after surgery (ERAS) protocols have known benefits in the inpatient setting, but little is known about their impact in the subsequent outpatient setting. On discharge, multimodal analgesia has been discontinued, nerve blocks and pain pumps have worn off, and patients enter a substantially different physical environment, potentially resulting in a rebound effect. The objective of this study was to investigate the effect of ERAS protocol implementation on outpatient opioid use and recovery. METHODS: Patients who underwent abdominally based microsurgical breast reconstruction before and after ERAS implementation were reviewed retrospectively. Ohio state law mandates that no more than 7 days of opioids may be prescribed at a time, with the details of all prescriptions recorded in a statewide reporting system, from which opioid use was determined. RESULTS: A total of 105 patients met inclusion criteria, of which 46 (44 percent) were in the pre-ERAS group and 59 (56 percent) were in the ERAS group. Total outpatient morphine milligram equivalents used in the ERAS group were less than in the pre-ERAS group (337.5 morphine milligram equivalents versus 668.8 morphine milligram equivalents, respectively; p =0.016). This difference was specifically significant at postoperative week 1 (p =0.044), with gradual convergence over subsequent weeks. Although opioid use was significantly less in the ERAS group, pain scores in the ERAS group were comparable to those in the pre-ERAS group. CONCLUSIONS: The benefits of ERAS protocols appear to extend into the outpatient setting, further supporting their use to facilitate recovery, and highlighting their potential role in helping to address the prescription opioid abuse problem. CLINICAL QUESTION/LEVEL OF EVIDENCE: Therapeutic, III.

来源:Plast Reconstr Surg,查看原文。版权归原作者所有。

引用

  1. Rendon JL, Hodson T, Skoracki RJ, et al. Enhanced Recovery after Surgery Protocols Decrease Outpatient Opioid Use in Patients Undergoing Abdominally Based Microsurgical Breast Reconstruction. Plast Reconstr Surg. 2020. PMID: 32097300. doi:10.1097/PRS.0000000000006546

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。